chrisvoncsefalvay/vaers-outcomes huggingface dataset:
had positive Covid test; had positive Covid test; This is a spontaneous report received from a non-contactable reporter(s) (Physician).  A 61-year-old male patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "OSA" (unspecified if ongoing). Concomitant medication(s) included: PAXIL [PAROXETINE HYDROCHLORIDE]; TAMSULOSIN; TADALAFIL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 21May2022, outcome "recovering" and all described as "had positive Covid test". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: Patient had negative Covid tests/ had positive Covid test; positive, notes: Patient had negative Covid tests/ had positive Covid test. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  Clinical course: Patient had negative Covid tests, felt better, then on 21May began to feel cough, headache, and had positive Covid test.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on plausible dose -event relationship post vaccination and no other alternate explanation the causal role of BNT162B2 cannot be excluded for the reported LOE events
REDNESS AND SWELLING(SOFTBALL SIZE)AT INJECTION SITE.  LOSS OF APPETITE, FEVER, DIARRHEA AND VOMITING.  8:00PM APPROXIMATELY.  TREATMENT:  BENADRY 50MG IM GIVEN IN OFFICE, DEXAMETHASONE 8MG IM GIVEN IN OFFICE, MEDROL DOSE PACK ORAL PRESCRIPTION, BENADRYL 25 MG ORAL PRESCRIPTION
Woke up in the middle of the night with body tremors with breathing difficulty, severe headache, sweating, and high fever.
This case was reported by a healthcare professional and described the occurrence of injection site redness in a subject of unspecified age and gender who was vaccinated with Flulaval, GlaxoSmithKline for prophylaxis.  On an unspecified date the subject received an unspecified dose of Flulaval (unknown).  At an unspecified time after vaccination with Flulaval, the subject experienced injection site redness.  At the time of reporting the outcome of the event was unspecified.
This case was reported by a healthcare professional and described the occurrence of syncopal attack in a 64-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medications included Calcium Supplements, TYLENOL, ZOCOR, BONIVA, COUMADIN, ALLEGRA and MIRALAX. On 20 October 2008 the subject received a dose of FLULAVAL at 0.5 ml in an unknown deltoid. On 20 October 2008, 30 minutes after vaccination with FLULAVAL, the subject experienced a syncopal episode. The healthcare professional considered the event was life threatening and clinically significant (or requiring intervention). At the time of reporting the outcome of the event was improved. The healthcare professional considered the event was probably related to vaccination with FLULAVAL. A statement in the text of the report read: The cold packs were not frozen upon delivery. Tag alert indicated that the product was okay. Days later at room temperature, the Tag Alert still says okay. Monitored in the emergency room and released.
Chills, fever, body aches less than 24 hours, that lasted about 2 weeks. Around end of April, both hands developed a rash and within a week, skin completely peeled off, like a snake shedding its skin. Hives/welts came out on torso and arms; lips and eyes swelled.  Treated w/Prednisone  Followed up w/Primary Care Dr., Cardiologist, Allergist, Dermatologist and Rheumatologist
Fever, tiredness, trouble breathing, hoarseness, rash on hand, weakness, dizziness and shortness of breath without excessive movement.
Information has been received from a registered nurse concerning a patient at an elementary school who was vaccinated with a dose of varicella virus vaccine live. Subsequently the patient developed a mild case of breakthrough varicella. There was no product quality complaint involved. Additional information has been requested.
Chest pain, nonradiating - possible myocarditis. Admitted to hospital for observation
Red swelling around injection site 24 hours after injection size of half dollar red itching, hurt to touch for 7 days - redness for 14 days.
Fever, body aches, chills, vomiting, chest pressure, headache, upset stomach, mental confusion. It was fine for the most part in a day and a half. The headache and chest pain lingered for two days.
After booster patient used bathroom and was having difficulty breathing. Use rescue inhaler to help breath.  Someone came in the bathroom and saw him struggling to breath and called a nurse who called 911 Patient was transported and admitted to the hospital.  Patient was admitted to ICU and then placed in a regular room.  As of 3 days later the patient is still in the hospital.  I have reached out to facility to get more info but no return call yet
injection arm turned blue and black; injection arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (injection arm turned blue and black) and VACCINATION SITE PAIN (injection arm soreness) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included CETIRIZINE HYDROCHLORIDE (ZIRTEC) for Allergy, VITAMIN A [RETINOL], ATORVASTATIN and MONTELUKAST for an unknown indication.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, the patient experienced VACCINATION SITE DISCOLOURATION (injection arm turned blue and black) and VACCINATION SITE PAIN (injection arm soreness). At the time of the report, VACCINATION SITE DISCOLOURATION (injection arm turned blue and black) and VACCINATION SITE PAIN (injection arm soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication were not reported.   This case was linked to MOD-2021-154043 (Patient Link).
hours post vaccination was told that the vaccine was not stored properly. Once home felt nauseous, severe headache, body ache and fatigue.
Pt had c/o pain in shoulder on day of administration and had difficulty sleeping. Day after imm., had 8 x 11 cm area warm, erythema, firm. ? Cellulitis.
No additional adverse events reported; a dose of Improperly Stored VARIVAX has been administered to a patient; This spontaneous report was received from a registered nurse referring to a 12-month-old patient of unknown gender. Concomitant medication, pertinent medical history, and drug reactions/allergies were not reported.   On 26-JAN-2022, the patient was vaccinated with a dose of improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 ml (route not reported; lot #U020244, expiration date 28-JUN-2023) for prophylaxis (product storage error).   The administered dose of the vaccine experienced a temperature excursion in the range 6 Fahrenheit degrees up to 14 Fahrenheit degrees (13.8 Fahrenheit degrees) for 1 hour 45 minutes and 0 seconds, and in the range 14 Fahrenheit degrees up to 46 Fahrenheit degrees (14.4 Fahrenheit degrees) for 0 hours 25 minutes and 0 seconds. There was no previous temperature excursion. No additional adverse events reported.
This spontaneous report as received from a reporter (details unspecified) refers to a 10 year old female patient with no medical history. On 15-JAN-2013 the patient was vaccinated with a first dose (1 dose) of GARDASIL (lot number expiry date and dose were not reported) intramuscular. No concomitant medication was taken. On 29-JAN-2013 (also reported as at fourteenth day after dose 1), the patient's fever was not quantified, the patient had headache and vomiting. No laboratory test was performed. The outcome of fever not quantified, headache and vomiting is unknown. Additional information is not expected.
A nurse practitioner reported that a 4 month old male received injections of Prevnar, Tripedia, IPV, and Comvax on 04/18/01. Within 24 hours of vaccination, the patient developed a generalized petechial rash and an injection site reaction described as "tenderness, redness, warmth, and swelling" at the Prevnar administration site. The reporter also noted that two other injection sites were red and inflamed. On 04/19/2001, the patient was "completely covered with purpura and petechia". He was hospitalized on 04/20/01, for three days with thrombocytopenia (platelet count not provided). the events were treated with immune globulin and the patient is "now doing fine". The follow up info was received on 05/23/2001 that indicated that the pt had  no preexisting illness at the time of vaccination and he received no vaccinations within 4 weeks of 04/18/2001. Follow-up info indicated that the child was seeing another primary care physician and that the reporter in this case had no follow up with the pt since the thrombocytopenia. The physician felt that the thrombocytopenia ha dstarted prior to the vaccination on 04/18/20001. In addition, the pt had no adverse events after the first dose of haemophilus B comjugate vaccine hepatitis b vaccine recombinant, administered at 2 months of age. It was also reported that the child "was expected to make a full recovery." this report was originally reported by a nurse practitioner. Follow-up info indicated that the pt's platelet count was 2000.
PC from grandmother "severe reaction". Complaints of baby restless and warm on 7/19 AM. Increased restlessness on 7/10, decreased appetite. Rash that appeared to be chicken pox on 7/14. Baby better today. Rash all over and early onset. Also received MMR that day.
Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021; Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Feb-2022 at 4:07 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 13-Feb-2022 at 4:07 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient age was reported as 35.14.  No concomitant medication was reported by reporter.  On 13-Feb-2021, Excursion time was 9 AM, temp was 32, total doses given for the day was 152, condition of vaccine prior to vaccination was not frozen, vaccine was moved to fridge on 09-Feb-2021, vial was moved to clinic on 13-JAN-2021. Vaccine BUD date was 10-Mar-2021. Number of vials sent to clinic 30.  It was reported that patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.    Vial was punctured right before administration.   No treatment medication was reported by reporter.   This case was linked to MOD-2022-566976 (Patient Link).
Information has been received from a 79 year old female consumer with a history of an allergic reaction to estrogen and no other pertinent medical history who on 22 Sep 2006 was vaccinated SC with a dose of Zostavax. Concomitant therapy included Pravachol. On 25 Sep 2006 the patient reported that she feels bad and has a prickly feeling going from hop down leg. As of 15 Dec 2006 she has not recovered. She reported that she has not seen a physician yet, but was scheduled to go in two weeks. There was no product quality complaint involved. Additional information has been requested.  This is in follow-up to report(s) previously submitted on 1/16/2007.  Follow-up information indicated that on 24-SEP-2006 the patient developed pricly painful sensations from hip down through entire leg both left and right sides.  She reported that it was difficult to walk or stand for short and long periods of time.  The was treated with IBUPROFEN and rest.  The patient recovered in March 2007.  Additional information is not expected.
Pt. received shot. Pt. called 9-1-13 and spoke to RPh on duty and reported bronchospasm = 6 hr after shot. Had to get Rx for albuterol inhaler. Currently doing fine. Pt. has hx of pneumonia. No other symptoms reported.
After the vaccine , I did have a cough and COVID test and felt it was allergies. Transient global amnesia in 24 hrs for 2-3 weeks on 23 Jun2021. I was on a field trip, I was coming back and felt weird and I could not remember some details. When I having dinner, my family said I repeated sentences 4 times over, went to ER in case it I was having a stroke. I was admitted for observation. I could read anything and I forgot to red. Amnesia lasted 24 hours.
Immediate rhinitis - fever onset 11-14-09 early am with intermittent fevers up to 104.5 on 11-14-09 -> 11-17-09 fatigue, tearing of eyes. Treatment supportive Motrin for fevers, cough onset 11-14-09 -> 11-17-09 nausea 11-16-09 -> 11-17-09.
severe anxiety, fear, restlessness, hyper, agitated, talking gibberish, not coherent, she was inconsolable
None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for an unknown indication.     No Medical History information was reported.   On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided by the reporter.  No treatment information was provided by the reporter.   This case was linked to MOD-2021-395985 (Patient Link).
Constant, low-mid grade headache daily since vaccination; Injection site randomly starting to hurt about 2 weeks after vaccination; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 16:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), sertraline hydrochloride (ZOLOFT), vitamin d nos (MANUFACTURER UNKNOWN) and unspecified birth control; all were taken for an unknown indication and within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 05Apr2021 the patient experienced constant, low-mid grade headache daily since vaccination. On an unknown date in Apr2021, about 2 weeks after vaccination, the patient experienced injection site randomly starting to hurt. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events constant, low-mid grade headache daily since vaccination and injection site randomly starting to hurt were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
p/vax pt exp swelling & redness at inj site & entire upper arm; addl information requested
After 1st vaccine a rash started on arms the next day. Used Anti Itch lotions and rash was eliminated by  February 25. Second dose taken on March 3rd. Rash and welts over arms back and legs started the same day. Saw PA on the 5th and prescribed Hydroxyzine 25mg and Triamcinolone ointment. Itching did not improve. PA saw patient on March 8th and prescribed Prednisone 25 mg, rash and itching were reduced over 7days but itching continues.
Approx. 1-2 hrs after flu vaccine, employee noticed arm where vacccine administered itching, then became aware of itching, stinging rash over entire body.Sts fever next day, abd discomfort since onset.Employee seen 5 days after symptom onset-treated with tapering dose Prednisone, Zantac OTC suggested.Offered eval by Wrk Md.11/20/07, empl. chose to come here to Empl. Health office.
At 14 days post vaccine, patient has a red, swollen, warm welt on her arm at the injection site. It isn't super large, but it looks like a typical vaccine reaction. She had the same reaction the day after her flu shot, about a month and a half ago, but this came up exactly 14 days after her covid vaccine.
Headache and eye ache Left side of shoulder radiates to left side of head, felt pulsating. Had black coffee for breakfast Exam normal Crackers and juice provided Discharged to home
Pt received yellow fever and typhoid vaccines at SHC on 02/01/05, 1-2 days post vaccination, she developed fatigue that has persisted for 3 months. For 7 days during this period she had diarrhea which responded to Cipro. SX persist at this writing.
(L) arm pain, aches, fever, malaise. 10-23-10 almost fainted, nausea, vomiting. To MD Tx with CIPRO.
very sore and painful for a few days; the last two doses she actually experience a delay type of hyper sensitive reaction.No seriousness to it, it resolve on its on; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (very sore and painful for a few days) and TYPE IV HYPERSENSITIVITY REACTION (the last two doses she actually experience a delay type of hyper sensitive reaction.No seriousness to it, it resolve on its on) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2022, the patient experienced PAIN (very sore and painful for a few days) and TYPE IV HYPERSENSITIVITY REACTION (the last two doses she actually experience a delay type of hyper sensitive reaction.No seriousness to it, it resolve on its on). In April 2022, PAIN (very sore and painful for a few days) and TYPE IV HYPERSENSITIVITY REACTION (the last two doses she actually experience a delay type of hyper sensitive reaction.No seriousness to it, it resolve on its on) had resolved.            No concomitant medication reported. No treatment information was provided.   This case was linked to MOD-2022-549689 (Patient Link).
started crying around MN 31MAR98 temp 104 R APAP;1hr later temp 101R;0730 temp 103 R motrin given;@ 10:00 temp 100.6 R, slept most of afternoon;no rash, no local rxn;
people saying there a side where there neck hurts; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of NECK PAIN (people saying there a side where there neck hurts) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NECK PAIN (people saying there a side where there neck hurts). At the time of the report, NECK PAIN (people saying there a side where there neck hurts) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications was not provided.  Treatment medications was not provided.  After vaccination patient had neck hurts.
Fever; body aches; headache; fatigue; a lot of pain on joints; pain all over his body; don't like to eat; don't like to walk; feel like I want to sleep; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), PAIN (body aches), HEADACHE (headache), FATIGUE (fatigue) and ARTHRALGIA (a lot of pain on joints) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no medical history provided).    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Jan-2021, the patient experienced PYREXIA (Fever), PAIN (body aches), HEADACHE (headache), FATIGUE (fatigue), ARTHRALGIA (a lot of pain on joints), PAIN (pain all over his body), DECREASED APPETITE (don't like to eat), GAIT DISTURBANCE (don't like to walk) and SOMNOLENCE (feel like I want to sleep). At the time of the report, PYREXIA (Fever), PAIN (body aches), HEADACHE (headache), FATIGUE (fatigue), ARTHRALGIA (a lot of pain on joints), PAIN (pain all over his body), DECREASED APPETITE (don't like to eat), GAIT DISTURBANCE (don't like to walk) and SOMNOLENCE (feel like I want to sleep) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.